Processing

Please wait...

Settings

Settings

Goto Application

1. WO1999057141 - IMMUNODIAGNOSTIC REAGENT FOR THE DETECTION OF MAEDI-VISNA VIRUS AND CAEV INFECTION

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

1 . A biotinylated peptide represented by the following formula:

[B, -L.] - (a) - CWHYX9X10YC- (b) - [L2- B2] (SEQ ID NO 83)

wherein B represents a biotinyl moiety and L represents an amide bond or an amino acid linker sequence containing from 1 to 5 amino acid residues, with either [B., -L-,] or [L2 -B2 ] present or both, and wherein (a) represents from none to the maximum number of contiguous amino acids located from position 1 to position 4 in the sequence represented by SEQ ID NO 1 2, and wherein (b) represents from none to the maximum number of contiguous amino acids located from position 1 3 to position 1 8 in the sequence represented by SEQ ID NO 1 2.

2. A biotinylated peptide according claim 1 having at least one of the following sequences:
[B, -Li ] -X^LDCWHYXgX^YCX^TSTX^X^ - [L2- B2] (SEQ ID NO 1 3)
[B, -Li ] -ELDCWHYX9X10YCX13TSTX17X18 - [L2- B2] (SEQ ID NO 1 4)
[B, -L, ] -LDCWHYX9X10YCX13TSTX17X18 - [L2- B2] (SEQ ID NO 1 5)
[BT -Li ] -DCWHYX9X10YCX13TSTX17X18 - [L2- B2] (SEQ ID NO 1 6)
[B, -L, ] -CWHYX9X10YCX13TSTX17X18 - [L2- B2] (SEQ ID NO 1 7)
[B, -L, ] -X^LDCWHYXgX^YCX^TSTX^ - [L2- B2] (SEQ ID NO 1 8)
[BT -L, ] -ELDCWHYX9X10YCX13TSTX17 - [L2- B2] (SEQ ID NO 1 9)
[B, -I, ] -LDCWHYX9X10YCX13TSTX17 - [L2- B2] (SEQ ID NO 20)
[B, -LT ] -DCWHYX9X10YCX13TSTX17 - [L2- B2] (SEQ ID NO 21 )
[BT -L, ] -CWHYX9X10YCX13TSTX17 - [L2- B2] (SEQ ID NO 22)
[B, -LI ] -X^LDCWHYXgX^YCX^TST - [L2- B2] (SEQ ID NO 23)
[B, -L, ] -ELDCWHYX9X10YCX13TST - [L2- B2] (SEQ ID NO 24)
[B. -L, ] -LDCWHYX9X10YCX13TST - [L2- B2] (SEQ ID NO 25)

[B, -L, ] -DCWHYX9X10YCX13TST - [L2- B2] (SEQ ID NO 26) [B, -Lil -CWHYX9X10YCX13TST - [L2- B2] (SEQ ID NO 27)
[B, -L-] -X^LDCWHYXgX^YCX^TS - [L2- B2] (SEQ ID NO 28)
IB, -Lil -ELDCWHYX9X10YCX13TS - [L2- B2] (SEQ ID NO 29)
[B. -L,] -LDCWHYX9X10YCX13TS - [L2- B2] (SEQ ID NO 30)
[B, -L,] -DCWHYX9X10YCX13TS - [L2- B2] (SEQ ID NO 31 )
[B, -Lil -CWHYX9X10YCX13TS - [L2- B2] (SEQ ID NO 32)
IB, -m -XT ELDCWHYX^OYCX^T - [L2- B2] (SEQ ID NO 33)
[B, -Lil -ELDCWHYX9X10YCX13T - [L2- B2] (SEQ ID NO 34)
[B, -L -LDCWHYX9X10YCX13T - [L2- B2] (SEQ ID NO 35)
[B, -Li - -DCWHYX9X10YCX13T - [L2- B2] (SEQ ID NO 36)
IB, -L,] -CWHYX9X10YCX13T - [L2- B2] (SEQ ID NO 37
[B, -Lil -X ELDCWHYXgX^YCX^ - [L2- B2] (SEQ ID NO 38)
IB, -Lil -ELDCWHYX9X10YCX13 - [L2- B2] (SEQ ID NO 39)
[B, -L,] -LDCWHYX9X10YCX13 - [L2- B2] (SEQ ID NO 40)
[B, -Lil -DCWHYX9X10YCX13 - [L2- B2] (SEQ ID NO 41 )
[B, -Lil -CWHYX9X10YCX13 - [L2- B2] (SEQ ID NO 42)
[B, "Lil -X^LDCWHYXgX^YC - [L2- B2] (SEQ ID NO 43)
IB, -L,] -ELDCWHYX9X10YC - [L2- B2] (SEQ ID NO 44)
[B, -L -LDCWHYX9X10YC - [L2- B2] (SEQ ID NO 45)
[B, -Lι- -DCWHYX9X10YC - [L2- B2] (SEQ ID NO 46)

[B -Lιl -CWHYX9X10YC - [L2- B2] (SEQ ID NO 47)
wherein
- XT represents Q or a conservative substitution of Q, preferably H,

- X9 represents Q or a conservative substitution of Q, preferably H,

- X10 represents H or a conservative substitution of H, preferably Q,

- X13 represents V or a conservative substitution of V, preferably I,

- X17 represents K or a conservative substitution of K, preferably R,

- X18 represents S or a conservative substitution of S, preferably T or A,

- B represents a biotinyl moiety,
- L represents an amide bond or an amino acid linker sequence containing from 1 to 5 amino acid residues, and with either [B, -L,] or [L2 -B2 ] being present or both.

3. A biotinylated peptide according to any of claims 1 to 2, having the following amino acid sequence:
B-GGQELDCWHYQHYCVTSTKS (SEQ ID NO 85)

4. A biotinylated peptide according to any of claims 1 to 3, whereby the two cysteine (C) residues present in the amino acid sequence are covalently linked to form an intramolecular cystine bridge.

5. A biotinylated peptide according to any of claims 1 to 4, whereby the biotinyl moiety is complexed to a streptavidin or avidin molecule.

6. A peptide composition comprising a biotinylated peptide according to any of claims 1 to 5, in combination with any other MW peptide or recombinant protein.

7. A peptide composition according to claim 6 comprising a biotinylated peptide according to any of claims 1 to 5 in combination with a recombinant MW gag (p25) polypeptide, or a fragment thereof, more specifically, in combination with the recombinant MW p25 protein as represented by SEQ ID NO 88 (figure 2).

8. A solid support upon which a biotinylated peptide according to any of claims 1 to 5, or a peptide composition according to any of claims 6 to 7, has been immobilized.

9. A method for the immunodetection of MW infection or CAEV infection in mammals, comprising the steps of:
- contacting a biological sample taken from said mammal with a biotinylated peptide according to any of claims 1 to 5, or with a peptide composition according to any of claims 6 to 7, under conditions allowing the formation of an immunological complex, and - detecting the presence of an immunological complex formed between said biotinylated peptide or said peptide composition and the anti-MW or anti-CAEV antibodies which may be present in the sample.

1 0. An immunodiagnostic kit for the detection of MW infection or CAEV infection in mammals, said kit comprising a biotinylated peptide according to any of claims 1 to 5, or a peptide composition according to any of claims 6 to 7.